36 Results

EF-14 phase III trial of Optune in glioblastoma published in Journal of Neuro-Oncology.- Novocure.

 Added 1 month ago

Novocure announced that the results of a retrospective post-hoc sub-group analysis of its EF-14 phase III pivotal trial in newly...

Phase III trial of DCVax-L shows continued benefits in brain cancer.- Northwest Biotherapeutics.

 Added 2 months ago

Northwest Biotherapeutics announced that updated blinded interim data from the Phase III trial of DCVax-L for Glioblastoma brain cancer through...

Interim phase III analysis of DCVax-L in glioblastoma published in Journal of Translational Medicine.- Northwest Biotherapeutics.

 Added 7 months ago

Northwest Biotherapeutics announced the publication of interim blinded survival data from its Phase III clinical trial of DCVax-L (gene therapy)...

Phase III GLOBE study of VB 111 + Avastin fails to meet endpoint in glioblastoma.- VBL Therapeutics.

 Added 10 months ago

VBL Therapeutics reported top-line results from its pivotal Phase III GLOBE study in patients with recurrent glioblastoma (rGBM) which was...

Induced pluripotent stem cells – a potential cancer vaccine

 Added 10 months ago

Induced pluripotent stem cells – a potential cancer vaccine

A new study from Stanford University may have found another use for iPS cells: priming the immune system to attack tumours.

Phase III trial results for Optune in glioblastoma published in JAMA Oncology.- Novocure.

 Added 11 months ago

Novocure announced that a detailed quality of life analysis of Novocure’s EF-14 phase III pivotal trial of Optune in combination...

Neuroblastoma study results show reduced pain

 Added 1 year ago

Results of study of Qarziba in high-risk neuroblastoma published in mAbs

FDA approves Mvasi (bevacizumab-awwb) biosimilar for non-small cell lung cancer, for metastatic colorectal cancer, glioblastoma, metastatic renal cell carcinoma and carcinoma of the cervix.- Amgen and Allergan.

 Added 1 year ago

Amgen and Allergan announced that the FDA has approved Mvasi (bevacizumab-awwb) for all eligible indications of the reference product, Avastin...

EU approves ch14.18/CHO, dinutuximab beta, as a treatment for high risk neuroblastoma in children. EUSA Pharma

 Added 1 year ago

EUSA Pharma announced that the European Commission (EC) has approved the antibody ch14.18/CHO, dinutuximab beta, for the treatment of high-risk...

Phase III GLOBE Study continues for ofranergene obadenovec (VB-111) in recurrent glioblastoma (rGBM).- VBL Therapeutics

 Added 1 year ago

VBL Therapeutics announced that the Independent Data Safety Monitoring Committee (DSMC) met to conduct its second safety review of the...

Load more